Treatment of anemia in patients with heart disease: A systematic review

Devan Kansagara, Edward Dyer, Honora Englander, Rongwei (Rochelle) Fu, Michele Freeman, David Kagen

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Background: The benefits of anemia treatment in patients with heart disease are uncertain. Purpose: To evaluate the benefits and harms of treatments for anemia in adults with heart disease. Data Sources: MEDLINE, EMBASE, and Cochrane databases; clinical trial registries; reference lists; and technical advisors. Study Selection: English-language trials of blood transfusions, iron, or erythropoiesis-stimulating agents in adults with anemia and congestive heart failure or coronary heart disease and observational studies of transfusion. Data Extraction: Data on study design, population characteristics, hemoglobin levels, and health outcomes were extracted. Trials were assessed for quality. Data Synthesis: Low-strength evidence from 6 trials and 26 observational studies suggests that liberal transfusion protocols do not improve short-term mortality rates compared with less aggressive protocols (combined relative risk among trials, 0.94 [95% CI, 0.61 to 1.42]; I2 = 16.8%), although decreased mortality rates occurred in a small trial of patients with the acute coronary syndrome (1.8% vs. 13.0%; P = 0.032). Moderate-strength evidence from 3 trials of intravenous iron found improved short-term exercise tolerance and quality of life in patients with heart failure. Moderate- to highstrength evidence from 17 trials of erythropoiesis-stimulating agent therapy found they offered no consistent benefits, but their use may be associated with harms, such as venous thromboembolism. Limitations: Few trials have examined transfusions in patients with heart disease, and observational studies are potentially confounded by indication. Data supporting iron use come mainly from 1 large trial, and long-term effects are unknown. Conclusion: Higher transfusion thresholds do not consistently improve mortality rates, but large trials are needed. Intravenous iron may help to alleviate symptoms in patients with heart failure and iron deficiency and also warrants further study. Erythropoiesis-stimulating agents do not seem to benefit patients with mild to moderate anemia and heart disease and may be associated with serious harms. Primary Funding Source: U.S. Department of Veterans Affairs.

Original languageEnglish (US)
Pages (from-to)746-757
Number of pages12
JournalAnnals of Internal Medicine
Volume159
Issue number11
StatePublished - Dec 3 2013

Fingerprint

Anemia
Heart Diseases
Hematinics
Iron
Observational Studies
Heart Failure
Mortality
Therapeutics
United States Department of Veterans Affairs
Exercise Tolerance
Information Storage and Retrieval
Venous Thromboembolism
Population Characteristics
Acute Coronary Syndrome
MEDLINE
Blood Transfusion
Health Status
Coronary Disease
Registries
Hemoglobins

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Treatment of anemia in patients with heart disease : A systematic review. / Kansagara, Devan; Dyer, Edward; Englander, Honora; Fu, Rongwei (Rochelle); Freeman, Michele; Kagen, David.

In: Annals of Internal Medicine, Vol. 159, No. 11, 03.12.2013, p. 746-757.

Research output: Contribution to journalArticle

Kansagara, D, Dyer, E, Englander, H, Fu, RR, Freeman, M & Kagen, D 2013, 'Treatment of anemia in patients with heart disease: A systematic review', Annals of Internal Medicine, vol. 159, no. 11, pp. 746-757.
Kansagara, Devan ; Dyer, Edward ; Englander, Honora ; Fu, Rongwei (Rochelle) ; Freeman, Michele ; Kagen, David. / Treatment of anemia in patients with heart disease : A systematic review. In: Annals of Internal Medicine. 2013 ; Vol. 159, No. 11. pp. 746-757.
@article{52678791b6224956b81ac81ee3cc6c09,
title = "Treatment of anemia in patients with heart disease: A systematic review",
abstract = "Background: The benefits of anemia treatment in patients with heart disease are uncertain. Purpose: To evaluate the benefits and harms of treatments for anemia in adults with heart disease. Data Sources: MEDLINE, EMBASE, and Cochrane databases; clinical trial registries; reference lists; and technical advisors. Study Selection: English-language trials of blood transfusions, iron, or erythropoiesis-stimulating agents in adults with anemia and congestive heart failure or coronary heart disease and observational studies of transfusion. Data Extraction: Data on study design, population characteristics, hemoglobin levels, and health outcomes were extracted. Trials were assessed for quality. Data Synthesis: Low-strength evidence from 6 trials and 26 observational studies suggests that liberal transfusion protocols do not improve short-term mortality rates compared with less aggressive protocols (combined relative risk among trials, 0.94 [95{\%} CI, 0.61 to 1.42]; I2 = 16.8{\%}), although decreased mortality rates occurred in a small trial of patients with the acute coronary syndrome (1.8{\%} vs. 13.0{\%}; P = 0.032). Moderate-strength evidence from 3 trials of intravenous iron found improved short-term exercise tolerance and quality of life in patients with heart failure. Moderate- to highstrength evidence from 17 trials of erythropoiesis-stimulating agent therapy found they offered no consistent benefits, but their use may be associated with harms, such as venous thromboembolism. Limitations: Few trials have examined transfusions in patients with heart disease, and observational studies are potentially confounded by indication. Data supporting iron use come mainly from 1 large trial, and long-term effects are unknown. Conclusion: Higher transfusion thresholds do not consistently improve mortality rates, but large trials are needed. Intravenous iron may help to alleviate symptoms in patients with heart failure and iron deficiency and also warrants further study. Erythropoiesis-stimulating agents do not seem to benefit patients with mild to moderate anemia and heart disease and may be associated with serious harms. Primary Funding Source: U.S. Department of Veterans Affairs.",
author = "Devan Kansagara and Edward Dyer and Honora Englander and Fu, {Rongwei (Rochelle)} and Michele Freeman and David Kagen",
year = "2013",
month = "12",
day = "3",
language = "English (US)",
volume = "159",
pages = "746--757",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "11",

}

TY - JOUR

T1 - Treatment of anemia in patients with heart disease

T2 - A systematic review

AU - Kansagara, Devan

AU - Dyer, Edward

AU - Englander, Honora

AU - Fu, Rongwei (Rochelle)

AU - Freeman, Michele

AU - Kagen, David

PY - 2013/12/3

Y1 - 2013/12/3

N2 - Background: The benefits of anemia treatment in patients with heart disease are uncertain. Purpose: To evaluate the benefits and harms of treatments for anemia in adults with heart disease. Data Sources: MEDLINE, EMBASE, and Cochrane databases; clinical trial registries; reference lists; and technical advisors. Study Selection: English-language trials of blood transfusions, iron, or erythropoiesis-stimulating agents in adults with anemia and congestive heart failure or coronary heart disease and observational studies of transfusion. Data Extraction: Data on study design, population characteristics, hemoglobin levels, and health outcomes were extracted. Trials were assessed for quality. Data Synthesis: Low-strength evidence from 6 trials and 26 observational studies suggests that liberal transfusion protocols do not improve short-term mortality rates compared with less aggressive protocols (combined relative risk among trials, 0.94 [95% CI, 0.61 to 1.42]; I2 = 16.8%), although decreased mortality rates occurred in a small trial of patients with the acute coronary syndrome (1.8% vs. 13.0%; P = 0.032). Moderate-strength evidence from 3 trials of intravenous iron found improved short-term exercise tolerance and quality of life in patients with heart failure. Moderate- to highstrength evidence from 17 trials of erythropoiesis-stimulating agent therapy found they offered no consistent benefits, but their use may be associated with harms, such as venous thromboembolism. Limitations: Few trials have examined transfusions in patients with heart disease, and observational studies are potentially confounded by indication. Data supporting iron use come mainly from 1 large trial, and long-term effects are unknown. Conclusion: Higher transfusion thresholds do not consistently improve mortality rates, but large trials are needed. Intravenous iron may help to alleviate symptoms in patients with heart failure and iron deficiency and also warrants further study. Erythropoiesis-stimulating agents do not seem to benefit patients with mild to moderate anemia and heart disease and may be associated with serious harms. Primary Funding Source: U.S. Department of Veterans Affairs.

AB - Background: The benefits of anemia treatment in patients with heart disease are uncertain. Purpose: To evaluate the benefits and harms of treatments for anemia in adults with heart disease. Data Sources: MEDLINE, EMBASE, and Cochrane databases; clinical trial registries; reference lists; and technical advisors. Study Selection: English-language trials of blood transfusions, iron, or erythropoiesis-stimulating agents in adults with anemia and congestive heart failure or coronary heart disease and observational studies of transfusion. Data Extraction: Data on study design, population characteristics, hemoglobin levels, and health outcomes were extracted. Trials were assessed for quality. Data Synthesis: Low-strength evidence from 6 trials and 26 observational studies suggests that liberal transfusion protocols do not improve short-term mortality rates compared with less aggressive protocols (combined relative risk among trials, 0.94 [95% CI, 0.61 to 1.42]; I2 = 16.8%), although decreased mortality rates occurred in a small trial of patients with the acute coronary syndrome (1.8% vs. 13.0%; P = 0.032). Moderate-strength evidence from 3 trials of intravenous iron found improved short-term exercise tolerance and quality of life in patients with heart failure. Moderate- to highstrength evidence from 17 trials of erythropoiesis-stimulating agent therapy found they offered no consistent benefits, but their use may be associated with harms, such as venous thromboembolism. Limitations: Few trials have examined transfusions in patients with heart disease, and observational studies are potentially confounded by indication. Data supporting iron use come mainly from 1 large trial, and long-term effects are unknown. Conclusion: Higher transfusion thresholds do not consistently improve mortality rates, but large trials are needed. Intravenous iron may help to alleviate symptoms in patients with heart failure and iron deficiency and also warrants further study. Erythropoiesis-stimulating agents do not seem to benefit patients with mild to moderate anemia and heart disease and may be associated with serious harms. Primary Funding Source: U.S. Department of Veterans Affairs.

UR - http://www.scopus.com/inward/record.url?scp=84890289353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890289353&partnerID=8YFLogxK

M3 - Article

C2 - 24297191

AN - SCOPUS:84890289353

VL - 159

SP - 746

EP - 757

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 11

ER -